Project Grant R01DK145692
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $272K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98108, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $1,677,898 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop fat and iron-corrected quantitative MRI T1 mapping as a non-invasive biomarker for evaluating chronic liver disease, particularly metabolic-associated steatohepatitis (MASH). The project addresses the clinical need for non-invasive assessment of liver pathology...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $850,096 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of S100A9+ macrophages and monocytic myeloid-derived suppressor cells in driving liver fibrosis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). The research leverages advanced multi-omics...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $743,862 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research on macrophage mitochondrial metabolism and metabolic dysfunction-associated steatotic liver disease (MASLD). The research investigates how alterations in macrophage composition and function contribute to MASH (metabolic dysfunction-associated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $889,856 on August 17, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate mechanisms by which metabolic-associated fatty liver disease (MASH) drives chronic kidney disease pathogenesis. The recipient will conduct three specific research aims over the performance period through April 30, 2031. Aim 1 confirms the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Administrators Of Tulane Educational Fund (Tulane University) $651,222 on August 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct basic research on molecular mechanisms driving metabolic dysfunction-associated steatohepatitis (MASH). The research investigates how ROBO1 (Roundabout Receptor 1), regulated by YAP and LHX2, promotes liver fibrosis in...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vanderbilt University Medical Center $874,741 on June 1, 2026, to investigate transcriptional mechanisms of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research identifies and characterizes transcription factors that regulate collagen production in hepatic stellate cells, a key driver of liver...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Seattle Children's Hospital, doing business as Seattle Children's Research Institute, $724,950 on May 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research to understand the mechanism of H3K9me3 heterochromatin-based silencing and selectively disrupt heterochromatin to improve the reprogramming of human fibroblasts into induced hepatocytes...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Beth Israel Deaconess Medical Center $164,484 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of DNAJC22 in metabolic dysfunction-associated steatotic liver disease (MASLD). The award funds research exploring DNAJC22, a gene of unknown function identified through genome-wide CRISPR-Cas9 screening and human genetic association studies...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of California, Los Angeles $128,235 on September 13, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research to discover mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD) through single nucleus RNA-sequencing analysis of cell-type and cellular subtypes in subcutaneous adipose tissue, visceral adipose...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $803,565 to the University of California, Davis on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and characterize an orally delivered nanodrug for metabolic disease treatment. The project targets metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus by addressing gut dysbiosis and restoring impaired signaling...